BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Blood

Volumn 127, Issue 23, 2016, Pages 2847-2855

  Dietrich, Sascha ^a,b,c   Pircher, Andreas ^d   Endris, Volker ^e   Peyrade, Frédéric ^f   Wendtner, Clemens Martin ^g   Follows, George A ^h   Hüllein, Jennifer ^b   Jethwa, Alexander ^b   Ellert, Elena ^e   Walther, Tatjana ^b   Liu, Xiyang ^b   Dyer, Martin J S ⁱ   Elter, Thomas ^j   Brummer, Tilman ^k   Zeiser, Robert ^l   Hermann, Michael ^m   Herold, Michael ^m   Weichert, Wilko ^e   Dearden, Claire ⁿ   Haferlach, Torsten ^o   Seiffert, Martina ^b   Hallek, Michael ^j   Von Kalle, Christof ^b   Ho, Anthony D ^a   Gaehler, Anita ^p   Andrulis, Mindaugas ^e   Steurer, Michael ^d   Zenz, Thorsten ^a,b   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g Klinikum Schwabing   (Germany)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j UNIVERSITY OF COLOGNE   (Germany)

^k UNIVERSITY OF FREIBURG   (Germany)

^l UNIVERSITY OF FREIBURG   (Germany)

^m HELIOS KLINIKUM ERFURT   (Germany)

ⁿ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^o MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^p LUZERNER KANTONSSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CXCL13 CHEMOKINE; EPIDERMAL GROWTH FACTOR; HEMOGLOBIN; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; RANTES; SOMATOMEDIN BINDING PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; RITUXIMAB; SULFONAMIDE;

ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG WITHDRAWAL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EVENT FREE SURVIVAL; HAIRY CELL LEUKEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; LOW DRUG DOSE; NEUTROPHIL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PAPILLOMA; PHOTOTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; SKIN CANCER; SQUAMOUS CELL CARCINOMA; THROMBOCYTE; THROMBOCYTE COUNT; TREATMENT DURATION; AGED; ANTAGONISTS AND INHIBITORS; LEUKEMIA, HAIRY CELL; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; RETREATMENT; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDOLES; LEUKEMIA, HAIRY CELL; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; RECURRENCE; RETREATMENT; RETROSPECTIVE STUDIES; RITUXIMAB; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84974623524     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-680074     Document Type: Article

References (42)

1. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115(1):21-28.
2. Dearden CE, Else M, Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leuk Lymphoma. 2011; 52(Suppl 2):21-24.
3. Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D; British Committee for Standards in Haematology. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant∗. Br J Haematol. 2012;156(2):186-195.
4. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107(12):4658-4662.
5. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-2315.
6. Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119(1):192-195.
7. Boyd EM, Bench AJ, van 't Veer MB, et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol. 2011;155(5):609-612.
8. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426-433.
9. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
10. Kim T, Kim J, Lee MG. Inhibition of mutated BRAF in melanoma [letter]. N Engl J Med. 2010;363(23): 2261-2262.
11. Dietrich S, Hüllein J, Hundemer M, et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol. 2013;31(19):e300-e303.
12. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012; 366(21):2038-2040.
13. Peyrade F, Re D, Ginet C, et al. Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica. 2013;98(2):e20-e22.
14. Follows GA, Sims H, Bloxham DM, et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol. 2013;161(1):150-153.
15. Urnova ES, Al'-Radi LS, Kuz'mina LA, et al. Successful use of vemurafenib in a patient with resistant hairy cell leukemia [in Russian]. Ter Arkh. 2013;85(7):76-78.
16. Sári E, Nagy ZG, Baghy K, et al. Treatment of refractory hairy cell leukemia with a BRAFinhibitor: lessons to be learnt. Pathol Oncol Res. 2014;20(4):973-980.
17. Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373(18): 1733-1747.
18. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708-720.
19. Mandrekar SJ. Early phase trial designs and endpoints for targeted therapies in rare genotype subsets. Am Soc Clin Oncol Educ Book. 2014;34: e107-e110.
20. Samuel J, Macip S, Dyer MJ. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014;370(3):286-288.
21. Maurer H, Haas P, Wengenmayer T, Lübbert M, Duyster J, Zeiser R. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. Ann Hematol. 2014;93(8): 1439-1440.
22. Cheson BD, Fisher RI, Barrington SF, et al; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27): 3059-3067.
23. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012; 36(12):1796-1800.
24. Yaktapour N, Meiss F, Mastroianni J, et al. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014;124(11):5074-5084.
25. Callahan MK, Rampal R, Harding JJ, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med. 2012;367(24): 2316-2321.
26. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
27. Yart A, Laffargue M, Mayeux P, et al. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor. JBiolChem.2001;276(12):8856-8864.
28. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
29. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39.
30. Motti ML, De Marco C, Califano D, et al. Loss of p27 expression through RAS-.BRAF-. MAP kinase-dependent pathway in human thyroid carcinomas. Cell Cycle. 2007;6(22): 2817-2825.
31. Dietrich S, Hüllein J, Lee SC, et al. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood. 2015;126(8):1005-1008.
32. Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014;166(2):177-188.
33. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010; 468(7326):968-972.
34. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-977.
35. Poulikakos PI, Rosen N. Mutant BRAF melanomas-dependence and resistance. Cancer Cell. 2011;19(1):11-15.
36. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2):177-182.
37. Heidorn SJ, Milagre C, Whittaker S, et al. Kinasedead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
38. Grey A, Cooper A, McNeil C, O'Toole S, Thompson J, Grimison P. Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma. Intern Med J. 2014;44(6):597-600.
39. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877-1888.
40. Dooley AJ, Gupta A, Bhattacharyya M, Middleton MR. Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. Ther Adv Med Oncol. 2014;6(6):262-266.
41. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002; 359(9317):1577-1578.
42. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. NEngl JMed. 2001;344(14): 1052-1056.